You are receiving this message as a subscriber to the FDA HIV/AIDS electronic list serve. The purpose of the list serve is to relay important information about HIV/AIDS-related products and issues, including product approvals, significant labeling changes, safety warnings, notices of upcoming public meetings and alerts to proposed regulatory guidances for comment.
Please do not reply to this message.
The HHS Panel on Antiretroviral Guidelines for Adults and Adolescents has release updated Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents
Key additions and revisions to the guidelines include:
- New section on HIV and the older patient
- New table on cost of antiretroviral drugs
- Updated recommendations on initiation of antiretroviral therapy (ART) in treatment-naive individuals
- Expanded discussion of use of hormonal contraceptives in HIV-infected women
- Preliminary recommendations on coadministration of the newly approved hepatitis C virus (HCV) NS3/4A protease inhibitors (PIs) boceprevir and telaprevir
- Recommendations on “when to start” ART in HIV-infected individuals diagnosed with tuberculosis but not receiving ART
- Discussion of the role of effective ART in preventing HIV transmission
You can see a complete list of key updates to the guidelines at What’s New in the Guidelines?
Current federally approved HIV/AIDS medical practice guidelines, as well as other topical HIV-related information can be found on the AIDSinfo web site.
Richard Klein
Office of Special Health Issues
Food and Drug Administration
Kimberly Struble
Division of Antiviral Drug Products
Food and Drug Administration
| This email was sent to list-fda@xxxxxxxxxxx using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420 |  |
